Last updated: February 13, 2026
Market Overview and Price Projections for TLANDO
Introduction
TLANDO (testosterone undecanoate), developed by Besins Healthcare, was approved by the FDA in February 2019 for adult men with hypogonadism. It is an oral testosterone formulation designed for convenience, differentiating it from injectable or transdermal options. The drug targets a market primarily composed of men seeking testosterone replacement therapy (TRT).
Market Size and Key Players
Global TRT Market
The global TRT market was valued at approximately $3.8 billion in 2021 and is projected to reach $5.7 billion by 2026, at a compound annual growth rate (CAGR) of 8.4% [1]. North America dominates, accounting for more than 75% of the market, driven by increased awareness and diagnosis of hypogonadism and the availability of multiple treatment options.
Key Competitors
- Testosterone gels and patches: AndroGel, Testim, Axiron
- Injectable formulations: Depo-Testosterone, Aveed
- Pellets and implants: Testopel
- Oral formulations: TLANDO, risks of liver toxicity have historically deterred development of oral testosterone
Positioning of TLANDO
TLANDO aims to carve a niche in the oral TRT segment, emphasizing convenience and ease of administration. Its approval provided an alternative to injectable and topical therapies, which can have compliance issues.
Regulatory and Commercial Factors
- FDA approval: 2019, after a Phase 3 trial showing bioequivalence to testosterone undecanoate injections
- Manufacturing: Bayer and Lannett had interests; Besins secured rights after approval
- Prescriptions and Adoption: Initial uptake slowed due to safety concerns and reimbursement issues. Expansion depends on securing formulary inclusion and clinician acceptance
Price Analysis
Current Pricing Landscape
- Injectable testosterone: Range $60–$150 per dose, usually administered every 2–4 weeks
- Gels and patches: Range $300–$600 monthly
- TLANDO: List price approximately $700–$800 for a 30-day supply [2]
Price Positioning
TLANDO's price is higher than topical and injectable options. Its premium positioning is justified by convenience and oral administration. Price sensitivity is moderate; physicians often consider the total cost, not only list prices, for patient access.
Cost Comparison Table
| Treatment Type |
Approximate Monthly Cost |
Administration Frequency |
Key Advantages |
| TLANDO (oral) |
$700–$800 |
Daily |
Oral, no injections or patches |
| Gels (e.g., AndroGel) |
$300–$600 |
Daily |
Non-invasive, easy to use |
| Injections (e.g., Depo-Testosterone) |
$60–$150 per dose |
Every 2–4 weeks |
Cost-effective, long-lasting |
| Transdermal patches |
$400–$600 |
Daily |
Steady testosterone levels |
Price Projections and Market Dynamics
Short-term Outlook (2023–2025)
- Pricing Stability: Expect minimal change in list price, as generic versions of topical formulations compete aggressively.
- Market Penetration: Slow initial growth due to safety restrictions and physician familiarity with established treatments.
- Reimbursement Policies: Favoring less costly and well-established therapies may limit TLANDO's adoption unless negotiated reimbursement agreements improve.
Medium-term Outlook (2026–2030)
- Price Adjustment: Possible reduction in net price through manufacturer discounts, formulary negotiations, and increased competition.
- Market Expansion Factors:
- Increasing diagnosis rates of hypogonadism
- Patient preference for oral therapy
- Regulatory support for oral testosterone options, possibly including biosimilars or generics in the future
- Forecasted Price Range: Expected to settle in the $600–$700 per month range, aligning with premium oral therapies [3].
Key Market Risks and Opportunities
- Risks: Safety concerns related to oral testosterone (risk of hepatic toxicity), regulatory hurdles, and competition from improved topical formulations or injectables with longer dosing intervals.
- Opportunities: Growing awareness of hypogonadism, potential for combination therapies, and increased insurance reimbursement favoring oral treatments.
Key Takeaways
- TLANDO entered a mature, competitive TRT market with steady growth prospects.
- Its higher price point reflects its convenience but faces pressure from generic topical therapies.
- Market expansion depends heavily on clinician adoption, patient preference, and reimbursement strategies.
- Price projections suggest minor reductions over time as competition and biosimilars emerge, with monthly costs stabilizing around $600–$700.
Frequently Asked Questions
1. How does TLANDO compare to injectable testosterone in terms of cost and convenience?
Injectable testosterone typically costs $60–$150 per dose, administered every 2–4 weeks, and requires healthcare provider administration. TLANDO costs about $700–$800 monthly, taken daily, offering greater convenience but at a higher total expense.
2. What are the main safety concerns with oral testosterone therapies like TLANDO?
Oral testosterone can pose risks of hepatic toxicity, endocrine suppression, and cardiovascular events. However, formulations like TLANDO are designed to minimize liver exposure, with safety profiles comparable to other options.
3. What factors influence TLANDO's market adoption?
Physician familiarity with existing therapies, insurance reimbursement policies, safety perception, and patient preference for oral over injectable or topical forms.
4. Are there any biosimilars or generics planned for TLANDO?
As of 2023, no biosimilars or generics for TLANDO are available. Generic topical formulations dominate the market, exerting price pressure.
5. What is the outlook for TLANDO's price in the next five years?
Prices are expected to stabilize around $600–$700 monthly, contingent on competitive pressures, regulatory developments, and reimbursement strategies.
References
[1] MarketsandMarkets. "Testosterone Replacement Therapy Market by Application, Distribution Channel, and Region." 2022.
[2] GoodRx. "TLANDO pricing and comparison." 2023.
[3] EvaluatePharma. "Oral testosterone market analysis." 2022.
